New rheumatoid arthritis drug candidate begins first human tests
NCT ID NCT07182656
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage study is testing a new drug called CIGB-814 for safety and how the body processes it. 70 healthy volunteers aged 18-45 will receive either the drug or a placebo as a single or multiple injections. The goal is to see if it is safe enough to test in people with rheumatoid arthritis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CIGB-814
- What this could lead to
- If successful, this could lead to a new treatment option for rheumatoid arthritis that helps control the disease.
- What could go wrong
- This is a very early Phase 1 trial in healthy people, not patients. It only tests safety and dosing, not whether it works for arthritis. Many early-stage drugs fail to show benefit later.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 101149, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple blood test flag heart risk in rheumatoid arthritis?
- Learning to Self-Care: a new approach to ease RA stiffness?
- Can a specialized hand exercise protocol restore grip and ease pain in rheumatoid arthritis?
- Can less be more? trial tests cutting RA medication doses
- Can a new pill tame rheumatoid arthritis when standard drugs fail?
- Can two common drugs tame rheumatoid arthritis?